The present invention relates to a medical device and method for treatment of blood vessels. More particularly, the present invention relates to an endovascular thermal treatment sheath for treating blood vessels such as varicose veins and method for using the same.
Veins can be broadly divided into three categories: the deep veins, which are the primary conduit for blood return to the heart; the superficial veins, which parallel the deep veins and function as a channel for blood passing from superficial structures to the deep system; and topical or cutaneous veins, which carry blood from the end organs (e.g., skin) to the superficial system. Veins have thin walls and contain one-way valves that control blood flow. Normally, the valves open to allow blood to flow into the deep veins and close to prevent back-flow into the superficial veins. When the valves are malfunctioning or only partially functioning, however, they no longer prevent the back-flow of blood into the superficial veins. This condition is called reflux. As a result of reflux, venous pressure builds within the superficial system. This pressure is transmitted to topical veins, which, because the veins are thin walled and not able to withstand the increased pressure, become dilated, tortuous or engorged.
In particular, venous reflux in the lower extremities is one of the most common medical conditions of the adult population. It is estimated that venous reflux disease affects approximately 25% of adult females and 10% of adult males. Symptoms of reflux include varicose veins and other cosmetic deformities, as well as aching and swelling of the legs. Varicose veins are common in the superficial veins of the legs, which are subject to high pressure when standing. Aside from being cosmetically undesirable, varicose veins are often painful, especially when standing or walking. If left untreated, venous reflux may cause severe medical complications such as bleeding, phlebitis, ulcerations, thrombi and lipodermatosclerosis (LDS). When veins become enlarged, the leaflets of the valves no longer meet properly. Blood collects in the superficial veins, which become even more enlarged. Since most of the blood in the legs is returned by the deep veins, and the superficial veins only return about 10%, they can be removed without serious harm. Non-surgical treatments of the superficial veins may include elastic stockings or elevating the diseased legs. However, while providing temporary relief of symptoms, these techniques do not correct the underlying cause, that is, the faulty valves. Permanent treatments include surgical excision of the diseased segments, ambulatory phlebectomy, and occlusion of the vein through chemical or thermal means, or vein stripping to remove the affected veins.
Surgical excision requires general anesthesia and a long recovery period. Even with its high clinical success rate, surgical excision is rapidly becoming an outmoded technique due to the high costs of treatment and complication risks from surgery. Ambulatory phlebectomy involves avulsion of the varicose vein segment using multiple stab incisions through the skin. The procedure is done on an outpatient basis, but is still relatively expensive due to the length of time required to perform the procedure.
Chemical occlusion, also known as sclerotherapy, is an in-office procedure involving the injection of an irritant chemical into the vein. The chemical acts upon the inner lining of the vein walls causing them to occlude and block blood flow. Although a popular treatment option, severe complications can result, such as skin ulceration, anaphylactic reactions and permanent skin staining. Treatment is limited to veins of a particular size range. In addition, there is a relatively high recurrence rate due to vessel recanalization.
Endovascular thermal therapy is an alternative surgical treatment that is less invasive compared to other surgical treatments and may be used to treat venous reflux diseases. This technique involves delivering thermal energy generated by laser, radio or microwave frequencies to causing vessel ablation or occlusion. Typically a sheath, fiber or other delivery system is percutaneously inserted into the lumen of the diseased vein. Thermal energy is then delivered to the vein wall or blood (depending on the device) as the energy source is withdrawn from the diseased vein.
A treatment sheath is placed into the great saphenous vein, the large subcutaneous superficial vein of the leg and thigh, at a distal location. The sheath is then advanced to within a few centimeters of the point at which the great saphenous vein enters the deep vein system, the sapheno-femoral junction. Typically, a physician will measure the distance from the insertion or access site to the sapheno-femoral junction on the surface of the patient's skin. This measurement is then transferred to the treatment sheath using tape, a marker or some other visual indicator to identify the insertion distance on the sheath shaft. Other superficial veins may also be accessed depending on the origin of reflux.
The treatment sheath is placed using either ultrasonic guidance or fluoroscopic imaging. The physician inserts the sheath into the vein using a visual mark on the sheath as an approximate insertion distance indicator. Ultrasonic or fluoroscopic imaging is then used to guide final placement of the tip relative to the junction. Positioning of the sheath tip relative to the sapheno-femoral junction or other reflux point is very important to the procedure because the sheath tip position is used to confirm correct positioning of the fiber when it is inserted and advanced. Current sheath tips are often difficult to clearly visualize under ultrasonic guidance.
Once the treatment sheath is properly positioned, a flexible optical fiber is inserted into the lumen of the sheath and advanced until the fiber tip extends distally beyond the sheath tip. The laser generator is then activated causing laser energy to be emitted from the distal end of the optical fiber. The energy reacts with the blood in the vessel and causes the blood to boil, thereby producing hot steam bubbles. The gas bubbles transfer thermal energy to the vein wall, causing damage to the endothelium and eventual vein collapse. While the laser remains turned on, the sheath and optical fiber are slowly withdrawn until the entire diseased segment of the vessel has been treated.
Currently available sheaths for endovascular laser treatment of reflux have several drawbacks. Prior art sheaths are designed such that the distal end portion of the fiber extends by approximately 1 cm beyond the distal end of the treatment sheath. Extension beyond the distal end of the sheath is necessary in order to avoid overheating of the polymer sheath tip by the laser energy, which may result in melting and other damage. Ensuring a sufficient distance between the fiber tip and sheath tip avoids any chance of overheating. While extending the energy emitting portion of the fiber beyond the distal end of the sheath avoids overheating, it leaves the fragile fiber tip unprotected and exposed within the vein. The exposed optical fiber tip is often damaged during the procedure as it is being withdrawn through the vein. Blood build up and charring on the energy-emitting face of the fiber tip often results in compromised energy delivery and tip degradation due to intensive heat. A degraded tip will often break leaving unwanted fragments of the optical fiber tip behind in a patient's body after treatment.
In addition to damage to the exposed laser emitting face of the optical fiber tip, a fiber that extends past the sheath tip may inadvertently come into contact with the vessel wall. Even unintended and unwanted contact between the optical fiber tip and the inner wall of the vessel can result in vessel perforation and extravasation of blood into the perivascular tissue. This problem is documented in numerous scientific articles including “Endovenous Treatment of the Greater Saphenous Vein with a 940-nm Diode Laser: Thrombotic Occlusion After Endoluminal Thermal Damage By Laser-Generated Steam Bubble” by T. M. Proebstle, Md., in J of Vasc. Surg., Vol. 35, pp. 729-736 (2002), and “Thermal Damage of the Inner Vein Wall During Endovenous Laser Treatment: Key Role of Energy Absorption by Intravascular Blood” by T. M. Proebstle, Md., in Dermatol. Surg., Vol. 28, pp. 596-600 (2002), both of which are incorporated herein by reference.
When the fiber inadvertently contacts the vessel wall during treatment, intense direct laser energy is delivered to the vessel wall rather than indirect thermal energy created as the blood is converted into gas bubbles. Laser energy in direct contact with the vessel wall can cause the vein to perforate at the contact point and surrounding area. Blood escapes through these perforations into the perivascular tissue, resulting in post-treatment bruising and associated discomfort.
Another problem with currently available sheaths is the difficulty in visualizing the distal end of the exposed fiber, which is very important in correctly positioning the treatment device. Although the sheath may be designed to be ultrasonically visible, it is often difficult for a physician to know where the tip of the optical fiber is in relation to the edge of the sheath. Incorrect placement may result in either incomplete occlusion of the vein or non-targeted thermal energy delivery to the deep femoral vein. Energy that is unintentionally directed into the deep venous system may result in deep vein thrombosis (DVT) and its associated complications including pulmonary embolism (PE).
Therefore, it is desirable to provide an endovascular treatment device and method which protects the energy delivery portion of the energy delivery device from even inadvertent direct contact with the inner wall of the vessel during the emission of energy to ensure consistent thermal heating across the entire vessel circumference, thus avoiding vessel perforation, incomplete vessel collapse, and damage to the optical fiber tip.
According to the principles of the present invention, an endovascular treatment sheath for use with an energy delivery device, such as an optical fiber, is provided. The sheath is designed to be inserted into a blood vessel and includes a longitudinal shaft lumen for receiving the optical fiber. The distal end of the sheath includes a heat insulative tip, which protects the optical fiber tip during the delivery of laser energy through the optical fiber.
In one aspect of the invention, the heat insulative tip may be made of ceramic material, which enables the tip to be heat resistant and echogenic. In another aspect of the invention, the heat insulative tip may be made of a glass material. In yet another aspect of the invention, the insulating tip may be made of a high-temperature resistant polymer.
The heat insulative tip of the present treatment sheath surrounds and protects the energy emitting face of the optical fiber and prevents the light emitting face from inadvertently contacting the inner wall of the vessel, thereby preventing vessel perforation and extravasation of blood into the perivascular tissue.
The present invention is illustrated in
The treatment sheath 2 is a tubular structure that is preferably composed of a flexible, low-friction material such as nylon. Endovenous treatment sheaths are typically 45 centimeters in length, although 60 and 65 centimeter sheaths are also well known in the art. The sheath 2 typically has an outer diameter of 0.079 inches and an inner diameter of about 0.055 inches, although other diameters can be used for different optical fiber sizes. The insulating tip 27 is located at the distal portion of the sheath 2. The insulating tip 27 can have a tapered outer profile. Preferably, only the distal end of the insulating tip 27 has a tapered outer profile. As is well known in the art, the taper provides a smooth transition from the outer diameter of the insulating tip 27, approximately 0.079 inches, to the smaller outer diameter of the insulating tip 27 front face 43, approximately 0.055 inches. The taper aids in insertion and advancement of the sheath 2. The tapered tip section 12 may be as short or as long as practical in order to ensure ease of entry and advancement. Optimally, the tapered tip section 12 is approximately 0.137 inches in length (3.5 mm), but may range from 0 to 5 mm in length. The angle of the tapered tip may be approximately 5 degrees relative to the longitudinal axis of the sheath, but any suitable angle may be also be used.
As shown in
As further shown in
The insulating tip 27 provides a protective barrier between the vein wall and the light emitting face 37 of the optical fiber shaft 23 during endovenous laser treatment of a vessel, such that the light emitting face 37 of the fiber shaft 23 is never directly exposed to the vessel wall, thereby minimizing perforations of the vessel. The protective function of the insulating tip 27 also minimizes accumulation of blood on the fiber face 37, which is known to cause charring and increased temperatures at the distal region of the fiber. The insulating tip 27 is composed of a high temperature-resistant material which ensures that the distal end portion of the sheath shaft 7 does not degrade under the elevated temperatures. By protecting the fragile fiber tip 37 from the vessel wall and from increased temperatures due to blood build-up, the risk of fiber damage, breakage and malfunction is reduced.
The insulating tip 27 and the sheath shaft 7 are permanently attached together at bonding zone 29, as shown in
The length of the bonding zone 29 is approximately 0.080 inches. The length between the front face 43 of the insulating tip 27 and the distal most edge of the insulating tip 27/sheath shaft 7 bonding zone 29 is approximately 0.670 inches. The length between the front face 43 of the insulating tip 27 and the proximal most edge of the bonding zone 29 is approximately 0.750 inches.
The insulating tip 27 component is illustrated in
The insulating tip 27 may be made from a machine-able ceramic, Macor, but finished components could also be molded. Although the tip 27 of the present invention is described herein as being made from a ceramic material, any heat insulative material may be used as the insulating tip 27. The heat insulative material is a material that is both heat-resistive which provides high resistance and structural integrity against high temperature and thermally non-conductive. Such material includes, but not limited to ceramic material, glass, high temperature resistant polymers, carbon, or the like.
The tip 27 of the present invention may contain fluoroscopically visible materials, such as radiopaque fillers, including tungsten or barium sulfate for increased visibility under fluoroscopic imaging. Alternatively or in addition, the tip 27 may have an ultrasonically visible filler such as hollow microspheres which create internal air pockets to enhance the reflective characteristics of the tip 27. With any of these embodiments, the ultrasonic and/or fluoroscopic visibility of sheath tip 27 provides the physician with the option of positioning the sheath tip 27 within the vessel using image guidance. Specifically, the heat insulative sheath tip 27 is more ultrasonically visible than the bare fiber near the light emitting face 37. In one embodiment, the heat insulative sheath tip 27 is also more ultrasonically visible than the shaft 7 of the treatment sheath.
In
A micropuncture sheath/dilator assembly is then introduced into the vein over the guidewire (104). A micropuncture sheath dilator set, also referred to as an introducer set, is a commonly used medical kit, for accessing a vessel through a percutaneous puncture. The micropuncture sheath set includes a short sheath with internal dilator, typically 5-10 cm in length. This length is sufficient to provide a pathway through the skin and overlying tissue into the vessel, but not long enough to reach distal treatment sites. Once the vein has been access using the micropuncture sheath/dilator set, the dilator and 0.018 inches guidewire are removed (106), leaving only the micropuncture introducer sheath in place within the vein (106). A 0.035 inches guidewire is then introduced through the introducer sheath into the vein. The guidewire is advanced through the vein until its tip is positioned near the sapheno-femoral junction or other starting location within the vein (108).
After removing the micropuncture sheath (110), a treatment sheath/dilator set is introduced into the vein and advanced over the 0.035 inches guidewire and advanced to 1 to 2 centimeters below the point of reflux, typically until the tip of the treatment sheath is positioned near the sapheno-femoral junction or other reflux point (112). Unlike the micropuncture introducer sheath, the treatment sheath is of sufficient length to reach the location within the vessel where the laser treatment will begin, typically the sapheno-femoral junction. Typical treatment sheath lengths are 45 and 65 cm. Positioning of the treatment sheath 2 is confirmed using either ultrasound or fluoroscopic imaging. The insulative tip 27 is designed to be clearly visible under either ultrasound or fluoroscopy. Once the treatment sheath/dilator set is correctly positioned within the vessel, the dilator component and guidewire are removed from the treatment sheath (114, 116).
The energy delivery device 10 is then inserted into the treatment sheath lumen and advanced until the energy delivery portion is surrounded by the heat insulative tip of the treatment sheath (118). If the fiber assembly has a connector lock 60 as shown in
The physician may optionally administer tumescent anesthesia along the length of the vein (122). Tumescent fluid may be injected into the peri-venous anatomical sheath surrounding the vein and/or is injected into the tissue adjacent to the vein, in an amount sufficient to provide the desired anesthetic effect and to thermally insulate the treated vein from adjacent structures including nerves and skin. Once the vein has been sufficiently anesthetized, laser energy or the like is applied to the interior of the diseased vein segment 49. The laser generator (not shown) is turned on, and as illustrated in
The physician manually controls the rate at which the sheath 2 and optical fiber 10 are withdrawn. As an example, it takes approximately 3 minutes to treat a 45 centimeter vein segment 49, and it requires a pullback rate of about one centimeter every four seconds. The laser energy produces localized thermal injury to the endothelium and vein wall 51 causing occlusion of the vein. The laser energy travels down the optical fiber shaft 23 through the energy-emitting face 37 of the optical fiber shaft 23 and into the vein lumen, where thermal energy contacts the blood, causing hot bubbles of gas to be created in the bloodstream. The gas bubbles expand to contact the vein wall 51, along a 360 degree circumference, thus damaging vein wall 51 tissue, causing cell necrosis, and ultimately causing collapse of the vessel.
Misdirected delivery of laser energy may result in vessel wall perforations where heat is concentrated and incomplete tissue necrosis where insufficient thermal energy is delivered. The endovascular treatment device of the present invention with a optical fiber shaft 23 that is protected by an insulating tip 27 avoids these problems by preventing inadvertent contact between the face 37 of the optical fiber shaft 23 and the vessel's inner wall 51 as the sheath 2 and optical fiber 10 are withdrawn through the vessel. The insulating tip 27 extends over and is spaced radially away from the light emitting face 37 of the optical fiber shaft 23 to prevent even inadvertent vessel wall contact. Although thin, the insulating tip 27 provides the necessary barrier between the vessel wall 51 and the optical fiber face 37 to prevent unequal laser energy delivery and fragmentation of the optical fiber shaft 23.
As illustrated in
The procedure for treating the varicose vein is considered to be complete when the desired length of the target vein has been exposed to laser energy. Normally, the laser generator is turned off when the face 37 of the optical fiber shaft 23 is approximately 3 centimeters from the access site. The physician can monitor the location of the face 37 relative to the puncture site in two different ways. Once the physician has been alerted to the proximity of the distal end of the insulating tip 27 at the access site by optional depth markers on the sheath 2, the physician continues to pull back the sheath 2 and optical fiber 10 until the bonding zone 29 appears at the access site indicating that the light emitting face 37 of the optical fiber 10 will be approximately 3 centimeters below the skin opening. At this point, the generator is turned off and the sheath 2 and optical fiber 10 can then be removed from the body.
The invention disclosed herein has numerous advantages over prior art treatment devices and methods. The endovascular sheath with its heat insulative tip and method of the present invention provides increased integrity of the treatment sheath by shielding the heat caused by laser energy from traveling upstream and burning the treatment sheath. The present device also provides optimized visibility under ultrasonic imaging modalities. This enhanced visibility of the insulating tip 27 of the sheath 2 leads to increased accuracy during final positioning of the device near the sapheno-femoral junction.
Finally, the insulating tip 27 of the present invention protects the delicate optical fiber shaft 23 during the endovenous laser treatment therapy, which prevents the optical fiber tip 37 from inadvertently contacting the vessel wall, thereby avoiding the problems described above, such as incomplete treatment, vessel perforations, or fragmentation, thereby further enhancing the endovenous laser therapy treatment.
Also veins other than the great saphenous vein can be treated using the method described herein.
The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many modifications, variations, and alternatives may be made by ordinary skill in this art without departing from the scope of the invention. Those familiar with the art may recognize other equivalents to the specific embodiments described herein. Accordingly, the scope of the invention is not limited to the foregoing specification.
This application is a continuation-in-part of U.S. application Ser. No. 11/777,198, filed Jul. 12, 2007, which is a continuation of U.S. application Ser. No. 10/613,395, filed Jul. 3, 2003, now U.S. Pat. No. 7,273,478, which claims priority under 35 U.S.C. Section 119(e) to U.S. Provisional Application Ser. No. 60/395,218 filed Jul. 10, 2002, all of which are incorporated herein by reference. This application is also a continuation-in-part of U.S. application Ser. No. 10/836,084, filed Apr. 30, 2004, which claims priority under 35 U.S.C. Section 119(e) to U.S. Provisional Application Ser. No. 60/516,156 filed Oct. 31, 2003, all of which are incorporated herein by reference. This application is also a continuation-in-part of U.S. application Ser. No. 11/362,239, filed Feb. 24, 2006, which is a continuation of U.S. application Ser. No. 10/316,545, filed Dec. 11, 2002, now U.S. Pat. No. 7,033,347, all of which are incorporated herein by reference. This application also claims priority under 35 U.S.C. Section 119(e) to U.S. Provisional Application Ser. No. 60/914,240, filed Apr. 26, 2007, which is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
60395218 | Jul 2002 | US | |
60516156 | Oct 2003 | US | |
60914240 | Apr 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10613395 | Jul 2003 | US |
Child | 11777198 | US | |
Parent | 10316545 | Dec 2002 | US |
Child | 11362239 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11777198 | Jul 2007 | US |
Child | 12109835 | US | |
Parent | 10836084 | Apr 2004 | US |
Child | 10613395 | US | |
Parent | 11362239 | Feb 2006 | US |
Child | 10836084 | US |